

ARTISAN-SNM 2-Year Clinical Study Highlights

Study Overview


<p>PURPOSE</p> <p>Prospective, single-arm, pivotal study</p>	<p>POPULATION</p> <p>Urinary Urgency Incontinence (UUI)</p>	<p>SITES</p> <p>14 centers in the United States and 5 in Western Europe</p>
<p>SIZE</p> <ul style="list-style-type: none"> 129 patients implanted in a non-staged procedure 121 patients completed 2-year follow-up 	<p>ENROLLMENT CRITERIA</p> <ul style="list-style-type: none"> Failed or could not tolerate first and second-line therapies UUI demonstrated on a 3-day voiding diary including at least 4 or more urgency leaks over 3 days Excluding moderate to high levels of stress incontinence 	

PATIENT DEMOGRAPHICS

<p>AGE</p> <p>21 AVG: 59 86</p> <p>BMI</p> <p>18 AVG: 32 58</p>	<p>GENDER</p> <p>98% Female 2% Male</p>	<p>SECONDARY DIAGNOSIS</p> <ul style="list-style-type: none"> Urgency Frequency: 50% Stress Incontinence: 39% Fecal Incontinence: 32% 		
---	--	---	--	--

2-Year Outcomes

Significant Reductions in UUI Episodes



of implanted patients had **≥50%** reduction in UUI symptoms



82% reduction in UUI episodes across all study patients




82% of treatment responders had **≥75%** reduction in urgency leaks



37% of treatment responders were dry

Continued on back


Clinically Meaningful Improvements in Quality of Life




Over 3X
the criteria for clinically
meaningful improvement

10-point improvement is
clinically significant¹


High Rates of Patient Satisfaction




Charging is
"Easy"



Charging frequency
& duration is
"Acceptable"



"Satisfied"
with the therapy



Would undergo the
therapy **again** with same
expected results



““”

This therapy makes me feel young again because now I can do anything. I have more freedom to come and go as I please. I am very satisfied with this system.

Favorable Safety Profile

- Treatment with the Axonics® System was well tolerated with no serious device-related adverse events reported.
- At 2-year,
 - <2% of patients reported discomfort at the INS site
 - <1% rate of lead migration was observed
 - <2% rate of lead fracture was observed

1. Benson K, et al. NeuroUrol Urodyn. 2020

Company Data on file.

Important Safety Information: Implantation and use of the Axonics System incurs risk beyond those normally associated with surgery, some of which may necessitate surgical intervention. Results and experiences may vary and are unique to each patient. No promise or guarantee is made about specific results or experiences. For more information about safety and potential risks, go to: www.axonics.com/isi.

Caution: Federal law (USA) restricts this device to sale and use by, or on the order of, a physician.